anastrozole has been researched along with Carcinoma, Anaplastic in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Health-related quality of life (HRQOL), symptoms of depression, and adverse events (AEs) were compared between Japanese postmenopausal patients with hormone-sensitive breast cancer (BC) who received adjuvant tamoxifen, exemestane, or anastrozole in an open-labeled, randomized, multicenter trial designated as the National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04 substudy of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial." | 9.16 | Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N- ( Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H, 2012) |
| "Anastrozole, given in doses of 1 and 10 mg once daily, represents a well tolerated and effective therapeutic option for the treatment of postmenopausal women with advanced breast carcinoma who progress after tamoxifen treatment." | 9.08 | A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. ( Buzdar, AU; Jones, SE; Plourde, P; Vogel, CL; Webster, A; Wolter, J, 1997) |
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 7.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| "Anastrozole (Arimidex) is an oral nonsteroidal aromatase inhibitor which is active in recurrent breast cancer." | 6.69 | A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. ( Bell, J; Brunetto, VL; Lee, RB; Rose, PG; VanLe, L; Walker, JL, 2000) |
| "Health-related quality of life (HRQOL), symptoms of depression, and adverse events (AEs) were compared between Japanese postmenopausal patients with hormone-sensitive breast cancer (BC) who received adjuvant tamoxifen, exemestane, or anastrozole in an open-labeled, randomized, multicenter trial designated as the National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04 substudy of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial." | 5.16 | Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N- ( Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H, 2012) |
| "Anastrozole, given in doses of 1 and 10 mg once daily, represents a well tolerated and effective therapeutic option for the treatment of postmenopausal women with advanced breast carcinoma who progress after tamoxifen treatment." | 5.08 | A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. ( Buzdar, AU; Jones, SE; Plourde, P; Vogel, CL; Webster, A; Wolter, J, 1997) |
| "RCTs investigating 3 different anticancer strategies in metastatic breast cancer were identified: (1) new hormonal therapy, (2) new targeted therapies in hormone receptor positive tumours (everolimus or palbociclib), and (3) new anti-HER2 therapies." | 4.93 | Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy. ( Niraula, S; Ocana, A, 2016) |
| "New aromatase inhibitors (AI) (second-generation: formestane and fadrozole; third-generation: letrozole, anastrozole, vorozole, and exemestane) have been tested in several controlled clinical trials after tamoxifen failure in metastatic breast carcinoma (MBC)." | 4.82 | New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. ( Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Milella, M; Mottolese, M; Nisticò, C; Papaldo, P; Ruggeri, EM; Terzoli, E, 2005) |
| "The aim of this study was to determine whether the bone-resorption response to anastrozole differed according to initial patient age in postmenopausal women with breast cancer in a cross-sectional study." | 3.77 | Does anastrozole affect bone resorption similarly in early and late postmenopausal women? ( Cochrane, RA; Davie, MW; Powell, DE, 2011) |
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 3.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| ", versus a control group of healthy postmenopausal women): (a) healthy postmenopausal women receiving tamoxifen; (b) postmenopausal women who had received treatment for early breast cancer; (c) postmenopausal breast cancer patients on adjuvant tamoxifen therapy; (d) postmenopausal breast cancer patients on adjuvant anastrozole therapy." | 3.74 | Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer. ( Bell, R; Lewis, J, 2007) |
| "Anastrozole (Arimidex) is an oral nonsteroidal aromatase inhibitor which is active in recurrent breast cancer." | 2.69 | A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. ( Bell, J; Brunetto, VL; Lee, RB; Rose, PG; VanLe, L; Walker, JL, 2000) |
| "The majority of breast cancer patients who have estrogen receptor positive (ER(+)) tumors whose proliferation is reduced after estrogen deprivation by aromatase inhibitors (AI)." | 1.37 | Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer. ( Anderson, H; Buffa, FM; Detre, S; Dexter, T; Dowsett, M; Dunbier, AK; Ghazoui, Z; Harris, AL; Salter, J; Smith, IE, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manjunatha, N | 1 |
| Ganjekar, S | 1 |
| Mahendra, JV | 1 |
| Kilara, N | 1 |
| Srinivasa, R | 1 |
| Rimawi, MF | 1 |
| Schiff, R | 1 |
| Osborne, CK | 1 |
| Niraula, S | 1 |
| Ocana, A | 1 |
| Barker, LC | 1 |
| Brand, IR | 1 |
| Crawford, SM | 1 |
| Doyen, J | 1 |
| Italiano, A | 1 |
| Largillier, R | 1 |
| Ferrero, JM | 1 |
| Fontana, X | 1 |
| Thyss, A | 1 |
| O'Connor, SM | 1 |
| Beriwal, S | 1 |
| Dabbs, DJ | 1 |
| Bhargava, R | 1 |
| Powell, DE | 1 |
| Cochrane, RA | 1 |
| Davie, MW | 1 |
| Ghazoui, Z | 1 |
| Buffa, FM | 1 |
| Dunbier, AK | 1 |
| Anderson, H | 1 |
| Dexter, T | 1 |
| Detre, S | 1 |
| Salter, J | 1 |
| Smith, IE | 1 |
| Harris, AL | 1 |
| Dowsett, M | 1 |
| Inno, A | 1 |
| Basso, M | 1 |
| Vecchio, FM | 1 |
| Marsico, VA | 1 |
| Cerchiaro, E | 1 |
| D'Argento, E | 1 |
| Bagalà, C | 1 |
| Barone, C | 1 |
| Takei, H | 1 |
| Ohsumi, S | 1 |
| Shimozuma, K | 1 |
| Takehara, M | 1 |
| Suemasu, K | 1 |
| Ohashi, Y | 1 |
| Hozumi, Y | 1 |
| Carlini, P | 1 |
| Bria, E | 1 |
| Giannarelli, D | 1 |
| Ferretti, G | 1 |
| Felici, A | 1 |
| Papaldo, P | 1 |
| Fabi, A | 1 |
| Nisticò, C | 1 |
| Di Cosimo, S | 1 |
| Ruggeri, EM | 1 |
| Milella, M | 1 |
| Mottolese, M | 1 |
| Terzoli, E | 1 |
| Cognetti, F | 1 |
| Rundle, P | 1 |
| Rennie, I | 1 |
| Resnik, KS | 1 |
| DiLeonardo, M | 1 |
| Gibbons, G | 1 |
| van Nes, JG | 1 |
| Seynaeve, C | 1 |
| van de Velde, CJ | 1 |
| Nortier, JW | 1 |
| Matsumoto, C | 1 |
| Ishikawa, T | 1 |
| Momiyama, N | 1 |
| Chishima, T | 1 |
| Ichikawa, Y | 1 |
| Togo, S | 1 |
| Inui, K | 1 |
| Shimada, H | 1 |
| Bell, R | 1 |
| Lewis, J | 1 |
| Buzdar, AU | 1 |
| Jones, SE | 1 |
| Vogel, CL | 1 |
| Wolter, J | 1 |
| Plourde, P | 1 |
| Webster, A | 1 |
| Rose, PG | 1 |
| Brunetto, VL | 1 |
| VanLe, L | 1 |
| Bell, J | 1 |
| Walker, JL | 1 |
| Lee, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268] | Phase 2 | 104 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
| A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormon[NCT02730923] | Phase 1/Phase 2 | 72 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for anastrozole and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Targeting HER2 for the treatment of breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Ant | 2016 |
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 2005 |
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
3 trials available for anastrozole and Carcinoma, Anaplastic
11 other studies available for anastrozole and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Tardive dyskinesia associated with anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Female; Humans; Middle Ag | 2013 |
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma; Disease Progression; Endo | 2009 |
Aromatase inhibition in male breast cancer patients: biological and clinical implications.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aroma | 2010 |
Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
Topics: Anastrozole; Anesthetics, Combined; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Early Detection | 2010 |
Does anastrozole affect bone resorption similarly in early and late postmenopausal women?
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Brea | 2011 |
Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Cel | 2011 |
Anastrozole-related acute hepatitis with autoimmune features: a case report.
Topics: Acute Disease; Aged; Anastrozole; Antibodies, Antinuclear; Antineoplastic Agents, Hormonal; Aromatas | 2011 |
Photodynamic therapy for solitary retinal metastasis from breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Combined Modality Therapy | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormon | 2006 |
[A case of advanced breast cancer with multiple liver metastases resistant to chemotherapy responding to high-dose toremifene].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Dose-Response Relationshi | 2007 |
Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuv | 2007 |